
Loading, please wait...

Loading, please wait...

Q1: Who is Dr. Dharminder Nagar?
Dr. Nagar is the Managing Director of Paras Health and the newly appointed Co-Chair of the FICCI Healthcare Committee.
Q2: What are the main focus areas for the new Co-Chair?
His primary focus areas include AI-enabled healthcare delivery, improving infrastructure in smaller cities, and enhancing patient safety policies.
Q3: How many hospitals does Paras Health currently operate?
Under Dr. Nagar's leadership, Paras Health has expanded to include eight hospitals across northern and eastern India.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Dr. Dharminder Nagar, MD of Paras Health, is the new Co-Chair of the FICCI Healthcare Committee, focusing on digital health and infrastructure in Tier II/II...
8 months ago

Novel diimide and hydrazone scaffolds, particularly compound #C4, synergistically reactivate latent HIV-1 when combined with JQ1 or PKC activators. Demonstrating donor-matched proviral transcription ex vivo and non-canonical signaling, these findings advance shock and kill strategies toward reservoir eradication.
Today

A cross-sectional study reveals that maternal RSV vaccination coverage reached only 43.7% in Argentina, with maternal vaccine knowledge being the sole independent predictor of uptake. Clinicians play a crucial role in eliminating informational and structural barriers to optimize infant health.
Today

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Yesterday

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Yesterday